Amyotrophic Lateral Sclerosis with Frontotemporal Dementia (ALS-FTD)

Types
Causes
Symptoms
Diagnostic tests
Non-pharmacological treatments (therapies & others)
Drug treatments
Dietary molecular supplements
Immunity-booster / regenerative / stem-cell” drugs
Surgeries / procedures
Preventions
When to see doctors
What to eat and what to avoid
FAQs

Amyotrophic lateral sclerosis with frontotemporal dementia (ALS-FTD) is a condition where two problems happen together. ALS damages the nerve cells (motor neurons) that control muscles in the brain and spinal cord. Over time, this causes weakness, stiff or tight muscles, trouble speaking and swallowing, and finally trouble breathing. FTD (frontotemporal dementia) affects the front and side parts of the brain that manage personality, behavior, decision-making, language, and social skills. When both occur together, a person may have muscle weakness and breathing problems from ALS, plus changes in personality, judgment, language, or behavior from FTD. Up to about half of people with ALS have some problems with thinking or behavior, and a smaller group meet full criteria for FTD; the most common FTD type in ALS is the behavioral variant (bvFTD) (loss of empathy, apathy, impulsive or inappropriate actions, rigid routines, sweet cravings). Vanderbilt University Medical Center+3PLOS+3PMC+3

ALS-FTD is a condition where two illnesses happen together in the same person. One illness is amyotrophic lateral sclerosis (ALS), which slowly damages the nerve cells that move our muscles. The other illness is frontotemporal dementia (FTD), which affects the front and side parts of the brain and changes behavior, personality, decision-making, and language. When both are present, a person can have muscle weakness, slurred speech, and swallowing or breathing problems from ALS, and changes in behavior, judgment, emotions, or language from FTD. Many people with ALS or FTD have the same brain protein changes (often involving a protein called TDP-43), and they share important genetic links—especially a change in a gene named C9orf72. These links explain why the two conditions can overlap. PubMed+2PubMed+2

A frequent genetic link is a C9orf72 gene change (a repeat expansion), which is the most common known genetic cause of both ALS and FTD in many populations. Other ALS-FTD genes include TARDBP (TDP-43), FUS, and SOD1. Not everyone with these gene changes gets the disease, and many people with ALS-FTD have no identifiable genetic cause. JNNP+2BioMed Central+2

Other names

Doctors and articles may use different names for the same overlap condition. You might see: “ALS-FTD,” “FTD-ALS,” “FTD with motor neuron disease (FTD-MND),” “motor neuron disease with FTD,” or “frontotemporal lobar degeneration with MND.” All of these point to the same idea: a person has both degeneration of the motor system and frontotemporal dementia features. PubMed

Types

ALS-FTD is a spectrum. People can sit at different points along that spectrum, from mostly motor problems to mostly thinking/behavior problems. A widely used expert framework groups people into:

ALS with cognitive impairment (ALSci): thinking or language problems are present but do not meet full dementia criteria.
ALS with behavioral impairment (ALSbi): behavior and personality have changed, but not enough to call it dementia.
ALS-FTD: both ALS and full frontotemporal dementia coexist.
FTD with motor neuron disease (FTD-MND): someone first diagnosed with FTD later shows clear signs of ALS.

This framework helps doctors organize care and choose tests even though the boundaries can blur in real life. PMC

Causes

Important note: In medicine, “cause” often means a change in a specific gene that strongly raises risk. For ALS-FTD, genetic causes are the clearest. Other items below are associated factors supported by research, but they may not “cause” the condition by themselves.

C9orf72 repeat expansion
This is the most common known genetic cause linking ALS and FTD. It involves a repeated DNA sequence that expands too much, which harms nerve cells. Families can have both ALS and FTD because of this single gene change. PMC+1
SOD1 variants
Changes in the SOD1 gene can cause inherited ALS. SOD1 mostly causes ALS without dementia, but it is part of the shared genetic landscape and appears in ALS-FTD families in some series. PMC
TARDBP (TDP-43) variants
TARDBP changes can lead to abnormal TDP-43 protein handling, a hallmark seen in both ALS and many FTD cases. The ALS Association+1
FUS variants
FUS is another gene for RNA-binding and protein processing. Certain FUS changes are linked to ALS and sometimes to frontotemporal problems. Lippincott Journals
TBK1 variants
TBK1 helps control waste-removal pathways in cells (autophagy). Changes in TBK1 are strongly tied to ALS-FTD families. PMC
SQSTM1 (p62) variants
This gene is part of the cell’s protein-recycling system. Some changes are linked to ALS and FTD features. SpringerLink
OPTN variants
OPTN works with SQSTM1 in protein cleanup. Some variants are found in ALS and occasionally FTD. SpringerLink
VCP variants
VCP affects how cells dispose of damaged proteins. Certain variants appear across ALS, FTD, and related syndromes. SpringerLink
UBQLN2 variants
This gene helps manage misfolded proteins. Changes can cause ALS and have been reported with dementia features. SpringerLink
CHCHD10 variants
A mitochondrial gene tied to energy balance in nerve cells; variants can be seen in ALS-FTD families. PMC
GRN (progranulin) variants
GRN mutations are a well-known cause of FTD and sometimes show motor neuron features, contributing to the overlap. PubMed
MAPT (tau) variants
MAPT changes cause some FTD types and can rarely present with motor neuron signs, supporting the spectrum idea. PubMed
ANG variants
Angiogenin gene changes have been found in ALS and may be present in ALS-FTD kindreds. Frontiers
TUBA4A variants
A structural cell gene; variants have been reported in ALS and sometimes with FTD features. Semantic Scholar
CCNF variants
CCNF is part of protein degradation pathways; variants have been linked to ALS and FTD. Frontiers
MATR3 variants
This RNA-binding protein gene has been associated with ALS; some families show cognitive or behavioral change as well. Semantic Scholar
TIA1 variants
TIA1 mutations affect stress-granule dynamics and have been reported across ALS and FTD. Semantic Scholar
FIG4 variants
A gene involved in cell membrane trafficking; some variants link to ALS and FTD. Frontiers
KIF5A and NEK1 variants
These genes relate to cell transport and structural stability. Studies show associations with ALS and shared risk with FTD. ScienceDirect+1
Complex genetic risk (many small effects)
Beyond single strong mutations, large studies show many small genetic changes add up and partly overlap between ALS and FTD, reinforcing that they sit on a shared genetic spectrum. Nature

Symptoms

Progressive muscle weakness
Weakness usually starts in a hand, foot, or speech/swallow muscles and slowly spreads. Tasks like buttoning, climbing steps, or holding a pen become hard. (ALS feature.) PubMed
Muscle wasting (thinning)
As nerves die, muscles shrink. This is easy to see in the hands, shoulders, thighs, or tongue. (ALS feature.) PubMed
Muscle twitching and cramps
Small, rippling twitches (fasciculations) and painful cramps happen because motor neurons are irritated or dying. (ALS feature.) PubMed
Stiffness and spasticity
Reflexes become brisk, legs feel “tight,” and walking can look stiff when the upper motor system is involved. (ALS feature.) PubMed
Slurred or quiet speech
Speech may sound nasal, slurred, or soft from weak or uncoordinated tongue, lip, and throat muscles. (ALS feature.) PubMed
Swallowing problems
Chewing and swallowing become slow or unsafe. Food or drink may “go the wrong way,” causing coughs or weight loss. (ALS feature.) PubMed
Shortness of breath or weak cough
Breathing muscles weaken, first during sleep, then in daytime. People feel morning headaches, fatigue, or breathless with small efforts. (ALS feature.) Taylor & Francis Online
Apathy (loss of drive)
In ALS-FTD, a person may lose interest in hobbies, social life, or self-care. This is not laziness; it is a brain-behavior change. (FTD feature.) PubMed
Disinhibition
Saying or doing things without a filter (rude jokes, risky choices, overspending) can appear, even in once-reserved people. (FTD feature.) PubMed
Loss of empathy
Family may notice a “cold” or flat emotional response to others’ feelings. (FTD feature.) PubMed
Compulsive or repetitive behaviors
Pacing, rigid routines, or focusing on one food or activity can develop. (FTD feature.) PubMed
Poor judgment and planning
Bills, schedules, or step-by-step tasks get messy; the person struggles to weigh risks and benefits. (FTD feature.) PubMed
Word-finding trouble
It can be hard to recall names or common words. Speech may become slow and effortful. (Language-variant FTD feature.) PubMed
Understanding or grammar problems
Some people struggle to understand complex sentences or grammar, or they mix up word meanings. (Language-variant FTD feature.) PubMed
Executive function problems
Tasks needing mental flexibility—like shifting plans or multi-tasking—become difficult. This is common in ALS-FTD. PMC

Diagnostic tests

A) Physical examination (tests your clinician does in the room)

Neurologic exam for upper motor neuron signs
The doctor checks reflexes (often brisk), muscle tone (often tight), and the plantar response (Babinski sign). Together these point to upper motor system damage seen in ALS. PMC
Exam for lower motor neuron signs
The doctor looks for muscle wasting, twitches, and weakness in different body regions. Finding both upper and lower motor signs in several regions supports ALS. PMC
Cranial nerve and bulbar exam
Speech clarity, voice quality, swallowing safety, tongue strength, and gag are checked to look for “bulbar” ALS involvement. PMC
Gait, balance, and posture assessment
Walking pattern, foot drop, balance, and stability are observed. Spastic or weak patterns suggest motor pathway problems consistent with ALS. PMC
Behavioral observation and caregiver interview
Because insight can be limited in FTD, the clinician asks family about behavior, judgment, and social changes to screen for the dementia component. PubMed

B) “Manual” bedside tests (simple, low-tech measures)

Manual muscle testing (MMT)
The clinician gently resists your movements and grades strength on a 0–5 scale in many muscles to map the pattern and severity of weakness over time. (Standard neuro exam technique.)
Grip-strength (hand dynamometer)
A handheld device measures squeeze strength. Falling numbers over time match disease progression in the hands and arms. (Common clinical measure.)
Single-Breath Count (SBC)
You take a deep breath and count out loud as far as you can in one breath at a steady pace. Lower counts suggest weaker breathing muscles and may track with lung tests. It’s quick, cheap, and helpful in clinics without equipment. PMC+1
ALS Functional Rating Scale–Revised (ALSFRS-R)
This is a short questionnaire about daily function (speech, swallowing, walking, breathing). Scores drop as ALS advances and help monitor change and discuss supports. PMC
Edinburgh Cognitive and Behavioural ALS Screen (ECAS)
This brief paper-and-pencil test is designed for ALS. It focuses on the frontotemporal thinking skills (language, fluency, executive tasks) and also checks memory/visuospatial skills. It helps spot ALS-related cognitive or behavioral changes early. Taylor & Francis Online

(Other cognitive screens like ACE-III or MoCA are also useful in clinics that do not have ECAS.) PMC+1

C) Laboratory and pathological tests (tests to rule out mimics and confirm clues)

Routine blood tests to exclude look-alike conditions
Doctors often check blood counts, electrolytes, liver/kidney function, thyroid, vitamin B12, HIV, and syphilis tests, and sometimes serum protein studies. These help rule out treatable problems that can imitate ALS or cause cognitive symptoms. NICE
Genetic testing (C9orf72 and an ALS/FTD panel)
Blood or saliva can be tested for the C9orf72 repeat and other ALS/FTD genes (e.g., SOD1, TARDBP, FUS, TBK1, GRN, MAPT, etc.). Testing is most helpful when there is a family history or young onset. Genetic counseling is recommended. NCBI+1
Serum or CSF neurofilaments (NfL, pNfH)
These are nerve-cell proteins that rise when axons are injured. Levels are often high in ALS and can help separate ALS from mimics and give prognosis clues. They are supportive, not stand-alone tests. BioMed Central+2JNNP+2
CSF analysis (lumbar puncture) in atypical cases
Spinal fluid tests may help exclude inflammation or infection. In ALS-FTD, CSF can be normal or show only nonspecific changes; the main role is ruling out other diseases. NICE
Autoimmune and paraneoplastic screens (selective)
If symptoms are unusual or very rapid, doctors may check blood for rare immune-related causes that sometimes resemble ALS or FTD. These are uncommon but important to consider when the story doesn’t fit. NICE
Formal neuropsychological evaluation
Detailed testing of attention, language, memory, social cognition, and executive skills confirms the FTD component, guides care partners, and helps with legal/financial planning. ECAS, ACE-III, or MoCA can be part of this package. Taylor & Francis Online+1

D) Electrodiagnostic tests (tests that study nerves and brain pathways)

Nerve conduction studies (NCS)
Small electrical pulses test how fast and strong signals travel in nerves. In ALS, NCS are often near-normal or mildly changed and mainly help exclude other nerve diseases. Combined with EMG, they support the ALS diagnosis. PMC
Electromyography (EMG)
A tiny needle records muscle electrical activity. EMG shows patterns of ongoing denervation and reinnervation in several body regions—key evidence for ALS in accepted criteria. PMC
Transcranial magnetic stimulation (TMS) / MUNIX (selected centers)
TMS can show cortical hyperexcitability, which helps distinguish ALS from mimics in research-supported settings. MUNIX (Motor Unit Number Index) is a quick surface-EMG method that estimates the number of working motor units and tracks loss over time. These are supportive tools rather than first-line tests. ScienceDirect+1

E) Imaging tests (ways to look at the brain and tracts)

Brain MRI for FTD patterns
MRI can show shrinkage of the frontal and temporal lobes in FTD. The pattern can support the diagnosis and rule out strokes, tumors, or water on the brain. MRI is also important when new behavior or language symptoms appear. PubMed
FDG-PET (metabolic brain scan)
FDG-PET may show lower activity in the frontal and temporal lobes, which supports FTD when MRI is unclear. Doctors use it when the clinical picture is confusing. PMC
ALS-focused MRI markers (supportive, not diagnostic)
In ALS, MRI may show subtle corticospinal tract signal changes or diffusion-tensor (DTI) changes along the motor pathways. These findings can support the diagnosis at expert centers, but by themselves they are not enough to diagnose ALS. Frontiers+1

Non-pharmacological treatments (therapies & others)

each item includes: description (~150 words), purpose, mechanism.

multidisciplinary ALS-FTD clinic care
description: care from a coordinated team (neurology, respiratory therapy, speech-language pathology, dietetics, physical/occupational therapy, social work, psychology/psychiatry, palliative care) in one place or in tightly coordinated visits. they plan ahead for breathing, swallowing, mobility, communication, cognition/behavior, legal/financial and caregiver needs. purpose: improve quality of life, reduce complications, and extend survival by timely decisions (like when to start breathing support or feeding tube). mechanism: frequent, structured assessments catch problems early; coordinated plans implement evidence-based steps (NIV, high-calorie nutrition, fall prevention) at the right time. Practical Neurology
noninvasive ventilation (NIV; e.g., BiPAP) education and setup
description: mask-based breathing support used during sleep and later in the day as needed. purpose: ease breathlessness and improve sleep and daytime energy; NIV extends survival and quality of life in ALS. mechanism: assists weakened breathing muscles, reduces CO₂ retention, improves oxygen exchange, and rests the diaphragm at night. Practical Neurology
airway clearance & cough assistance
description: training in manually assisted cough, mechanical insufflation–exsufflation (“cough-assist”), suction, and positioning; regular oral care. purpose: reduce chest infections and hospitalizations. mechanism: devices and techniques temporarily increase airflow to move mucus; oral care reduces bacterial load that can be aspirated. Palliative Care Network of Wisconsin
speech-language therapy (SLP): speech, swallowing, & communication
description: SLP evaluates speech and swallowing, teaches safer swallowing strategies, and guides communication aids. purpose: reduce choking/aspiration risk, keep communication effective. mechanism: compensatory postures (e.g., chin-tuck), pacing, bolus size control, and texture changes; AAC (apps, eye-gaze devices) preserves communication as speech weakens. Evidence on thickened liquids is mixed; they may reduce aspiration in some contexts but can hurt hydration and enjoyment—use individualized decisions with an SLP. PMC+2JAMA Network+2
voice & message banking (early)
description: record words/phrases while speech is strong; create a synthetic or pre-recorded voice for later. purpose: maintain a familiar voice and personal messages when speech is lost. mechanism: banking software and AAC devices store and play customized speech.
nutrition therapy & high-calorie meal planning
description: dietitians design energy-dense, easy-to-swallow meals/snacks and schedule frequent small meals; monitor weight. purpose: prevent weight loss (a strong negative prognostic factor) and maintain strength. mechanism: high-calorie intake (sometimes high-fat) and texture modifications; evidence suggests high-calorie nutrition can help maintain weight and may improve outcomes in ALS. PubMed+1
PEG feeding education & timing discussion
description: early counseling about percutaneous endoscopic gastrostomy (PEG) before breathing function declines too far. purpose: assure safe nutrition/hydration, reduce choking, stabilize weight. mechanism: direct stomach feeding bypasses weak swallowing muscles; best outcomes when placed before severe respiratory weakness. JAMA Network
physical therapy: gentle aerobic activity & range-of-motion
description: tailored, low-to-moderate aerobic exercise, stretching, and contracture prevention; energy conservation training. purpose: reduce stiffness/spasticity, prevent contractures, improve mood and sleep, maintain function longer. mechanism: movement improves circulation, joint health, and reduces secondary pain from immobility.
occupational therapy & adaptive equipment
description: home and work task simplification, energy conservation, and assistive devices (grab-bars, raised toilet seats, modified utensils, shower chairs). purpose: preserve independence and safety in daily activities. mechanism: compensates for weakness, reduces fall and injury risk.
mobility aids & fall prevention
description: canes, walkers, ankle-foot orthoses, power wheelchairs; home safety review (rugs, lighting, ramps). purpose: avoid falls, conserve energy, maintain community access. mechanism: devices stabilize gait and compensate for foot-drop and proximal weakness.
behavioral & environmental strategies for FTD symptoms
description: routine-based days, simplified choices, external structure (calendars, reminders), limiting triggers for disinhibition, and caregiver coaching. purpose: lower agitation, impulsivity, wandering, and risky spending/behavior. mechanism: reducing cognitive load and environmental stress compensates for frontotemporal control deficits. AFTD
caregiver training & respite planning
description: teach safe transfers, choking first aid, device use, and behavior management; arrange respite. purpose: reduce caregiver burnout and injuries; maintain care quality. mechanism: skills plus rest periods sustain long-term home care.
sleep hygiene and positioning
description: elevation for reflux, side-lying to manage secretions, regular sleep schedule. purpose: improve sleep quality and morning headaches from hypoventilation. mechanism: posture and routine reduce airway obstruction and reflux micro-aspiration.
pseudobulbar affect (PBA) coping skills
description: education about sudden crying/laughing episodes, cueing, and breathing techniques. purpose: reduce embarrassment and social withdrawal. mechanism: anticipatory strategies and cueing blunt reflexive episodes; combine with medication when needed. American Academy of Neurology
mental health & palliative care support (early)
description: counseling for anxiety/depression, anticipatory grief, and values-based decisions; palliative care early to manage symptoms and plan ahead. purpose: improve quality of life and support difficult choices. mechanism: regular symptom review, goals-of-care discussions, and advance directives.
legal/financial and safety planning
description: power of attorney, healthcare proxy, driving cessation when unsafe, home safety checks. purpose: protect the person’s wishes and prevent harm. mechanism: formal decision-makers and hazard reduction.
respiratory infection prevention (vaccines & hygiene)
description: annual influenza and periodic pneumococcal vaccines; hand hygiene and caregiver illness policies. purpose: lower risk of pneumonia and hospitalizations. mechanism: immunization and exposure control reduce infections that people with weak cough cannot clear.
sialorrhea (drooling) behavioral strategies
description: posture (chin-tuck), scheduled swallows, oral suction devices, and oral care. purpose: reduce choking, skin irritation, and social discomfort. mechanism: gravity and timing plus suction decrease pooling of saliva; used before or alongside medications/injections. The ALS Association
communication access & decision aids
description: simplified, visual decision tools; caregivers learn to present either/or choices and confirm understanding. purpose: uphold autonomy despite FTD. mechanism: supports impaired executive function and language.
education about what NOT to do: diaphragm pacing
description: diaphragm pacing (surgically implanted electrodes) might sound helpful, but randomized trials in ALS showed harm or no benefit, so it should not be used in routine ALS care. purpose: prevent exposure to harmful procedures. mechanism: avoiding procedures shown to reduce survival in trials. The Lancet+2NCBI+2

Drug treatments

for each: long description (~150 words), drug class, usual dose/time, purpose, mechanism, key side effects.
note: always follow your clinician’s advice; doses may change for kidney/liver status, age, interactions, and goals of care.

riluzole
class: glutamate modulator. dose/time: 50 mg by mouth twice daily on an empty stomach. purpose: modestly prolongs survival and delays tracheostomy for many with ALS. mechanism: reduces glutamatergic excitotoxicity that injures motor neurons. side effects: nausea, fatigue, dizziness; rare liver enzyme elevations (monitor LFTs). notes: standard of care for most ALS unless contraindicated; benefits are small but meaningful when combined with multidisciplinary care. Amylyx
edaravone (IV or oral, Radicava ORS)
class: free-radical (oxidative stress) scavenger/antioxidant. dose/time: cycle dosing (e.g., 14 days daily, then 10 of 14 days each month per label for oral/IV). purpose: in selected patients, may slow functional decline on ALSFRS-R. mechanism: reduces oxidative damage to motor neurons. side effects: headache, bruising; sulfite sensitivity reactions; IV risks include line reactions. notes: patient selection matters; discuss realistic expectations. The ALS Association
tofersen (Qalsody®) — for confirmed SOD1-ALS
class: antisense oligonucleotide. dose/time: intrathecal loading doses, then monthly maintenance per label. purpose: for people with a pathogenic SOD1 mutation, tofersen lowers neurofilament (nerve-injury marker) and may slow decline; received accelerated FDA approval. mechanism: binds SOD1 mRNA and reduces toxic SOD1 protein. side effects: headache, back pain, CSF pleocytosis; procedure-related effects. notes: requires genetic testing and specialty centers. PMC
dextromethorphan/quinidine (for pseudobulbar affect)
class: NMDA/glutamate modulator + CYP inhibitor combination. dose/time: 20/10 mg twice daily. purpose: reduces sudden uncontrollable laughing/crying (PBA). mechanism: dextromethorphan acts on sigma-1 and NMDA pathways; quinidine boosts its level. side effects: dizziness, diarrhea; QT prolongation risk; drug interactions. American Academy of Neurology
SSRIs (e.g., sertraline, citalopram, escitalopram)
class: antidepressants. dose/time: start low (e.g., sertraline 25–50 mg daily) and titrate. purpose: help depression/anxiety and may dampen FTD behaviors (irritability, compulsions). mechanism: increases serotonin signaling in frontotemporal circuits. side effects: GI upset, sleep changes, hyponatremia; watch for activation. Psychiatry Online+1
trazodone
class: serotonin antagonist/reuptake inhibitor. dose/time: 25–50 mg at night; titrate. purpose: agitation and sleep problems in FTD/ALS. mechanism: serotonergic modulation with sedative properties. side effects: sedation, orthostasis.
atypical antipsychotics (e.g., quetiapine)
class: dopamine/serotonin antagonists. dose/time: low doses (e.g., quetiapine 12.5–25 mg at night) as needed for severe agitation/psychosis after non-drug measures and SSRIs. purpose: control dangerous agitation; avoid typical antipsychotics when possible. mechanism: reduces overactive limbic circuits. side effects: sedation, metabolic issues, QT risk; can worsen parkinsonism.
baclofen
class: GABA-B agonist antispasticity agent. dose/time: begin 5 mg 1–3×/day, titrate to effect. purpose: ease spasticity and cramps. mechanism: reduces excitatory neurotransmission in spinal cord. side effects: weakness, somnolence; caution in renal disease. notes: may combine with tizanidine at lower doses. BioMed Central+2PM&R KnowledgeNow+2
tizanidine
class: α2-adrenergic agonist antispasticity drug. dose/time: 2 mg at night, slowly titrate; often divided dosing. purpose: reduce spasms with potentially less weakness than baclofen. mechanism: presynaptic inhibition of motor neurons. side effects: dry mouth, hypotension, LFT elevations. Medscape
mexiletine (for painful muscle cramps)
class: sodium-channel blocker (antiarrhythmic). dose/time: 150 mg twice daily (commonly used trial dose); ECG review for QT. purpose: reduces cramp frequency and intensity in ALS. mechanism: stabilizes muscle membrane excitability. side effects: nausea, heartburn, rare arrhythmia risk. PMC
glycopyrrolate (for drooling)
class: anticholinergic. dose/time: 0.5–1 mg by mouth 2–3×/day; titrate. purpose: reduce sialorrhea. mechanism: lowers saliva production. side effects: dry mouth, constipation, urinary retention, confusion (less central than others). PMC
atropine ophthalmic drops (sublingual, off-label, for drooling)
class: anticholinergic. dose/time: 1% drop(s) under tongue as needed. purpose: short-acting drooling control. mechanism: anticholinergic drying effect. side effects: dry mouth, blurred vision; misuse may cause toxicity—use clinician guidance. PMC+1
scopolamine transdermal patch (for drooling/motion-type secretions)
class: anticholinergic. dose/time: 1 patch every 72 h. purpose: reduce drooling and secretions. mechanism: muscarinic blockade. side effects: confusion, constipation, urinary retention; caution in FTD. Palliative Care Network of Wisconsin
amitriptyline
class: tricyclic antidepressant. dose/time: 10–25 mg at night. purpose: helps drooling (drying effect), mood, and sleep. mechanism: anticholinergic and norepinephrine/serotonin reuptake inhibition. side effects: anticholinergic effects, QT risk. Muscular Dystrophy Association
botulinum toxin injections into salivary glands
class: neurotoxin chemodenervation (procedure with drug). dose/time: every 3–6 months by trained clinician. purpose: targeted control of severe drooling when pills fail. mechanism: temporarily blocks acetylcholine release in salivary glands to reduce saliva. side effects: dry mouth, swallowing changes; requires expertise. PMC
opioids for dyspnea and pain (e.g., low-dose morphine)
class: opioid analgesic. dose/time: low doses titrated carefully. purpose: relieve refractory breathlessness and pain. mechanism: reduces central sensation of air hunger; analgesia. side effects: constipation, sedation; use bowel regimen.
gabapentin/pregabalin (neuropathic pain, cramps)
class: calcium-channel α2δ ligands. dose/time: start low, titrate (e.g., gabapentin 100–300 mg at night). purpose: reduce neuropathic pain and nocturnal discomfort. mechanism: reduces excitatory neurotransmission. side effects: sedation, dizziness.
prokinetics or anti-reflux therapy (e.g., PPIs, alginates)
class: GI agents. dose/time: individualized. purpose: reduce reflux-related cough/aspiration. mechanism: decrease acid or improve gastric emptying. side effects: vary by agent.
melatonin
class: sleep-wake regulator. dose/time: 1–5 mg at night. purpose: sleep onset/maintenance with low interaction burden. mechanism: circadian modulation. side effects: vivid dreams, morning sleepiness.
edema/constipation protocols (laxatives, stool softeners)
class: GI supportive meds. dose/time: regular schedule, especially with anticholinergics or opioids. purpose: keep bowels moving; prevent impaction. mechanism: osmotic/softening action. side effects: bloating, cramps.

important update on AMX0035 (sodium phenylbutyrate/taurursodiol): this drug (Relyvrio) was voluntarily withdrawn by the manufacturer in 2024 after a confirmatory trial failed to show benefit; it is generally no longer available in many markets. PMC

Dietary molecular supplements

none of these cure or reliably slow ALS or FTD; evidence is mixed or negative. use them only if your clinician agrees, to avoid interactions and to focus on proven care (nutrition, NIV, riluzole/edaravone, symptom control).

coenzyme Q10 (CoQ10)
long description: antioxidant supporting mitochondrial function. trials in ALS have not shown clear benefit, including a Phase II program that did not justify Phase III. dose: varied in studies (often 300–3000 mg/day). function/mechanism: antioxidant electron carrier. PMC+1
vitamin E
long description: antioxidant; no survival benefit in ALS trials, though small biochemical changes reported. dose: often 400–800 IU/day in studies. function: reduces oxidative stress. PMC+1
creatine
long description: cellular energy buffer; ALS trials show no consistent functional or survival benefit; may help general strength/energy in other settings. dose: 3–5 g/day. function: supports ATP buffering. Dove Medical Press
vitamin D
long description: general bone/immune support; correct deficiency to prevent fractures and falls; no proof it slows ALS. dose: per labs (often 1000–2000 IU/day). mechanism: calcium/bone and immunomodulatory effects.
omega-3 fatty acids
long description: anti-inflammatory lipids; theoretical neuronal support; no confirmed ALS disease-modifying effect. dose: 1–3 g/day EPA/DHA. mechanism: membrane fluidity, anti-inflammatory signaling.
N-acetylcysteine (NAC)
long description: glutathione precursor; may thin mucus when nebulized; ALS-slowing effect unproven. dose: oral 600–1200 mg/day (varies). mechanism: antioxidant/ mucolytic. Palliative Care Network of Wisconsin
**B-complex / methylcobalamin (B12)
long description: standard B-complex supports nutrition; ultra-high-dose methylcobalamin (50 mg IM twice weekly) showed short-term functional slowing only in early-stage ALS in a Japanese RCT; broader benefit is unproven. dose: only under physician care. mechanism: axonal methylation/repair. JAMA Network
resveratrol / polyphenols
long description: antioxidant/anti-inflammatory; no ALS clinical proof; theoretical benefits. dose: varies.
magnesium
long description: sometimes tried for cramps; data for ALS cramps is limited; watch for diarrhea with high doses.
probiotics/fiber
long description: for bowel regularity, especially with anticholinergic or opioid meds; no ALS-modifying effect.

Immunity-booster / regenerative / stem-cell” drugs

important: these are not proven cures for ALS-FTD. several are experimental; some were not effective; one has accelerated approval for a specific gene; another has conditional approval in one country. please discuss clinical trials with your neurologist and avoid unregulated clinics.

tofersen (Qalsody®)
type: antisense gene therapy for SOD1-ALS (approved in the US via accelerated approval). dose: intrathecal per label. function/mechanism: suppresses mutant SOD1 protein to reduce motor-neuron injury; lowers neurofilament. note: requires confirmed SOD1 variant; not for general ALS. PMC
lenzumestrocel / NeuroNata-R® (autologous MSCs)
type: mesenchymal stem-cell therapy. status: conditionally approved in South Korea since 2014; not approved in US/EU; company discussing possible accelerated pathways. Evidence remains mixed and largely subgroup-based; global regulators want more proof. mechanism: proposed trophic/immune modulation. caution: availability and benefit remain uncertain outside Korea. MND Association+2ALS News Today+2
NurOwn® (MSC-NTF)
type: autologous stem-cell product. status: FDA advisory committee voted 17-1 against approval in 2023 due to lack of efficacy; not approved. mechanism: trophic/anti-inflammatory factors (theoretical). implication: not recommended outside trials. Reuters+1
BIIB078 (antisense for C9orf72)
type: antisense oligonucleotide targeting C9orf72 sense RNA. status: program discontinued after failure to show clinical benefit. mechanism: aimed to reduce toxic RNA/protein products of the repeat expansion. ALS News Today+1
masitinib (oral tyrosine-kinase inhibitor; investigational)
type: anti-inflammatory/ glial-modulating small molecule. status: earlier mixed results; a new Phase 3 trial was cleared to launch in 2025 (U.S./EU). mechanism: may reduce microglial activation. note: not approved; available only in trials. ALS News Today
ultra-high-dose methylcobalamin (vitamin B12) — early ALS only
type: neurotrophic support. status: short-term benefit in early ALS in a Japanese RCT; not a universal therapy; not ALS-FTD-specific. mechanism: supports axonal repair/methylation. dose: physician-directed IM injections only. JAMA Network

avoid “stem-cell clinics” that sell expensive, non-approved infusions without solid evidence—these can be risky and divert resources from proven care.

Surgeries / procedures

percutaneous endoscopic gastrostomy (PEG)
procedure: a small tube is placed through the abdominal wall into the stomach under endoscopy. why: secure nutrition/hydration and medication delivery when swallowing is unsafe or too tiring; helps maintain weight and reduces choking/aspiration during feeding. timing matters: discuss early, before breathing falls too low for safe anesthesia. JAMA Network
tracheostomy with invasive ventilation (selected cases)
procedure: a breathing tube is placed surgically in the neck and attached to a ventilator. why: for people choosing long-term full ventilatory support when NIV is no longer enough; requires 24/7 care and intensive planning.
botulinum toxin injections to salivary glands
procedure: ultrasound-guided injections into parotid/submandibular glands. why: reduce severe drooling when pills fail; repeat every 3–6 months. PMC
intrathecal baclofen pump placement (severe spasticity)
procedure: a pump is implanted under the skin to deliver baclofen directly to spinal fluid. why: treats spasticity not controlled by oral drugs with fewer systemic side effects. SAGE Journals
what not to choose routinely: diaphragm pacing
procedure: laparoscopic electrodes stimulate the diaphragm. why not: randomized trials showed no benefit and potential harm in ALS; do not use routinely. The Lancet+1

Preventions

vaccinate (influenza, pneumococcal) to prevent pneumonia. Practical Neurology
early NIV when recommended to prevent nighttime hypoventilation and CO₂ buildup. Practical Neurology
maintain weight with high-calorie nutrition to prevent frailty and pressure sores. SpringerLink
swallowing safety: SLP-guided strategies; individualized texture changes if needed; meticulous oral care. PMC
aspiration risk control: upright eating, small bites/sips, slow pace; stop when fatigued.
fall prevention: home modifications, mobility aids, supervised transfers.
pressure-injury prevention: cushions, repositioning, skin checks.
secretions management: scheduled suction/cough-assist, hydration, humidification. Palliative Care Network of Wisconsin
medication review: avoid drugs that worsen cognition (strong anticholinergics) or breathing suppressants unless clearly needed.
advance-care planning: clear decisions reduce crisis-driven choices.

When to see doctors

new or worsening shortness of breath, morning headaches, daytime sleepiness, or frequent nighttime awakenings → evaluate for NIV. Practical Neurology
choking, weight loss, dehydration, or long mealtimes → urgent SLP and dietitian review; discuss PEG. JAMA Network
rapid behavior change (unsafe spending, wandering, aggression) or severe depression/anxiety → neurology/psychiatry for FTD-informed care. AFTD
recurrent chest infections, thick secretions, or weak cough → airway-clearance plan and vaccines. Palliative Care Network of Wisconsin
uncontrolled drooling (skin breakdown/choking) → anticholinergics or botulinum toxin. PMC
painful cramps or spasticity → consider mexiletine, baclofen, or tizanidine. PMC+1

What to eat and what to avoid

aim for high-calorie, high-protein, soft, moist meals (eggs, fish, yogurt, nut butters), with frequent snacks. SpringerLink
add healthy fats (olive oil, avocado) to boost calories without large volumes.
use texture that matches your swallow: minced/soft solids if chewing weak; consider SLP-guided thickened liquids only if they clearly reduce aspiration for you. PMC
drink enough fluids—thickened liquids can reduce intake; monitor hydration. ERS Publications
time meals when you’re rested, upright, and with help if needed; stop if you get tired.
avoid hard, crumbly, or stringy foods (nuts, dry meat, tough bread) if they cause coughing. Roswell Park
limit alcohol; it worsens balance, sleep, and judgment.
treat reflux (smaller meals, don’t lie down right after eating).
consider PEG when oral intake isn’t safe/sufficient—PEG can supplement enjoyable small tastes by mouth. JAMA Network
work with your SLP and dietitian—individual plans beat one-size-fits-all. ScienceDirect

FAQs

is ALS-FTD hereditary?
sometimes. C9orf72 and a few other genes can run in families, but many people have no family history. genetic counseling can help decide about testing. JNNP
what symptoms make ALS-FTD different from “typical” ALS?
along with limb, speech, or breathing weakness, people may develop behavior changes, poor judgment, loss of empathy, rigid routines, language trouble, or eating sweet foods excessively—features of bvFTD. Vanderbilt University Medical Center
are there cures?
no cure yet. riluzole, edaravone, and in SOD1-ALS, tofersen, plus NIV, PEG, and specialized care can meaningfully help. Amylyx+2The ALS Association+2
does AMX0035 (Relyvrio) help?
it was withdrawn in 2024 after a trial failed to show benefit. PMC
can thickened liquids prevent pneumonia?
they can reduce aspiration in some settings, but evidence is mixed, and thickening can lower fluid intake; decisions should be individualized with an SLP. PMC+1
does exercise help or hurt?
gentle, tailored activity can help stiffness, mood, and function; avoid over-fatigue and heavy resistance.
how does NIV help?
it supports weak breathing muscles during sleep and later during the day, improving comfort and survival. Practical Neurology
should we consider diaphragm pacing?
no—randomized trials in ALS showed harm/no benefit; it is not recommended. The Lancet
what can help sudden crying or laughing (PBA)?
behavior strategies plus dextromethorphan/quinidine can help. American Academy of Neurology
what eases painful muscle cramps?
mexiletine lowers cramp frequency/intensity in ALS; discuss ECG risks. PMC
is there anything for drooling?
positioning/oral care first; then glycopyrrolate, atropine, scopolamine, amitriptyline; if severe, botulinum toxin injections to salivary glands. PMC
what about stem-cell therapies?
outside trials, no proven stem-cell treatment for ALS. NurOwn was not approved; NeuroNata-R is conditionally approved in South Korea only. Reuters+1
can high-calorie diets help?
they help maintain weight and may improve outcomes; meta-analyses show weight/BMI benefits even if survival effects vary. SpringerLink
do supplements cure ALS?
no supplement cures ALS. some (e.g., B12 at ultra-high dose) show limited, early-stage benefits; most (e.g., CoQ10, vitamin E, creatine) have no proven disease-slowing effect. Dove Medical Press+3JAMA Network+3PMC+3
what helps caregivers?
education (safe transfers, choking first aid), respite, social work support, and palliative care early—caregiver health is essential to good care.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 15, 2025.

PDF Documents For This Disease Condition

References

SaveSavedRemoved 0